Christopher Hoimes, DO

Publications

Talukder, Rafee, Dimitrios Makrakis, Leonidas N. Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Vadim S. Koshkin, et al. “Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.” Clin Genitourin Cancer 20, no. 2 (April 2022): 165–75. https://doi.org/10.1016/j.clgc.2021.12.012.

PMID
35078711
Full Text

Koshkin, Vadim S., Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam, Christopher T. Su, et al. “Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.” Cancer 128, no. 6 (March 15, 2022): 1194–1205. https://doi.org/10.1002/cncr.34057.

PMID
34882781
Full Text

Petrylak, Daniel P., Thomas W. Flaig, Nataliya Mar, Theodore Stewart Gourdin, Sandy Srinivas, Jonathan E. Rosenberg, Maria Guseva, Yao Yu, Sujata Narayanan, and Christopher J. Hoimes. “Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.” In Journal of Clinical Oncology, 40:435–435. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.435.

Full Text

Hoimes, Christopher J., Thomas W. Flaig, Sandy Srinivas, Nataliya Mar, Daniel P. Petrylak, Peter H. O’Donnell, Mehmet Asim Bilen, et al. “Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).” In Journal of Clinical Oncology, 40:TPS587–TPS587. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.tps587.

Full Text

Nebhan, Caroline A., Alessio Cortellini, Weijie Ma, Teja Ganta, Haocan Song, Fei Ye, Rebecca Irlmeier, et al. “Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.” Jama Oncol 7, no. 12 (December 1, 2021): 1856–61. https://doi.org/10.1001/jamaoncol.2021.4960.

PMID
34734989
Full Text

Nebhan, Caroline, Alessio Cortellini, Weijie Ma, Teja Ganta, Haocan Song, Fei Ye, Rebecca Irlmeier, et al. “239 Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged ≥80 years: a multicenter international cohort study.” In Journal for Immunotherapy of Cancer, 9:A257–A257. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.239.

Full Text

Pal, Sumanta K., Paul H. Frankel, Amir Mortazavi, Matthew Milowsky, Ulka Vaishampayan, Mamta Parikh, Yung Lyou, et al. “Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.” Jama Oncol 7, no. 10 (October 1, 2021): 1536–43. https://doi.org/10.1001/jamaoncol.2021.3441.

PMID
34436521
Full Text

Makrakis, Dimitrios, Rafee Talukder, Leonidas N. Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Vadim S. Koshkin, et al. “Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.” Bju Int, October 1, 2021. https://doi.org/10.1111/bju.15603.

PMID
34597472
Full Text

Smith, Daniel A., Ethan Radzinsky, Sree Harasha Tirumani, Ezgi Guler, Andrew Petraszko, Elias Kikano, Christopher J. Hoimes, and Nikhil H. Ramaiya. “Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.” Ajr Am J Roentgenol 217, no. 3 (September 2021): 613–22. https://doi.org/10.2214/AJR.20.24758.

PMID
33295801
Full Text

Shah, Neal R., Brandon Declouette, Kianoush Ansari-Gilani, Mohammad S. Alhomoud, Christopher Hoimes, Nikhil H. Ramaiya, and Ezgi Güler. “High-dose interleukin-2 therapy related adverse events and implications on imaging.” Diagn Interv Radiol 27, no. 5 (September 2021): 684–89. https://doi.org/10.5152/dir.2021.20503.

PMID
34559052
Full Text

Pages